PA2A4_NAJSG
ID PA2A4_NAJSG Reviewed; 126 AA.
AC Q6T179;
DT 02-SEP-2008, integrated into UniProtKB/Swiss-Prot.
DT 05-JUL-2004, sequence version 1.
DT 03-AUG-2022, entry version 73.
DE RecName: Full=Acidic phospholipase A2 4;
DE Short=svPLA2;
DE EC=3.1.1.4;
DE AltName: Full=Phosphatidylcholine 2-acylhydrolase;
DE Flags: Precursor; Fragment;
OS Naja sagittifera (Andaman cobra).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Lepidosauria; Squamata; Bifurcata; Unidentata; Episquamata; Toxicofera;
OC Serpentes; Colubroidea; Elapidae; Elapinae; Naja.
OX NCBI_TaxID=195058;
RN [1]
RP NUCLEOTIDE SEQUENCE [MRNA], X-RAY CRYSTALLOGRAPHY (1.86 ANGSTROMS) IN
RP COMPLEX WITH CALCIUM ION, COFACTOR, AND DISULFIDE BONDS.
RC TISSUE=Venom, and Venom gland;
RX PubMed=16269164; DOI=10.1016/j.toxicon.2005.08.008;
RA Jabeen T., Singh N., Singh R.K., Ethayathulla A.S., Sharma S.,
RA Srinivasan A., Singh T.P.;
RT "Crystal structure of a novel phospholipase A2 from Naja naja sagittifera
RT with a strong anticoagulant activity.";
RL Toxicon 46:865-875(2005).
CC -!- FUNCTION: Snake venom phospholipase A2 (PLA2) that exhibits strong
CC anticoagulant activity, which is not due to the catalytic activity.
CC PLA2 catalyzes the calcium-dependent hydrolysis of the 2-acyl groups in
CC 3-sn-phosphoglycerides.
CC -!- CATALYTIC ACTIVITY:
CC Reaction=a 1,2-diacyl-sn-glycero-3-phosphocholine + H2O = a 1-acyl-sn-
CC glycero-3-phosphocholine + a fatty acid + H(+); Xref=Rhea:RHEA:15801,
CC ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:28868,
CC ChEBI:CHEBI:57643, ChEBI:CHEBI:58168; EC=3.1.1.4;
CC Evidence={ECO:0000255|PROSITE-ProRule:PRU10035, ECO:0000255|PROSITE-
CC ProRule:PRU10036};
CC -!- COFACTOR:
CC Name=Ca(2+); Xref=ChEBI:CHEBI:29108;
CC Evidence={ECO:0000305|PubMed:16269164};
CC Note=Binds 1 Ca(2+) ion. {ECO:0000305|PubMed:16269164};
CC -!- SUBUNIT: Monomer.
CC -!- SUBCELLULAR LOCATION: Secreted.
CC -!- TISSUE SPECIFICITY: Expressed by the venom gland.
CC -!- SIMILARITY: Belongs to the phospholipase A2 family. Group I subfamily.
CC D49 sub-subfamily. {ECO:0000305}.
CC ---------------------------------------------------------------------------
CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC ---------------------------------------------------------------------------
DR EMBL; AY443496; AAR16428.1; -; mRNA.
DR PDB; 1YXH; X-ray; 1.86 A; A=1-126.
DR PDBsum; 1YXH; -.
DR AlphaFoldDB; Q6T179; -.
DR SMR; Q6T179; -.
DR PRIDE; Q6T179; -.
DR BRENDA; 3.1.1.4; 8192.
DR EvolutionaryTrace; Q6T179; -.
DR GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell.
DR GO; GO:0005509; F:calcium ion binding; IEA:InterPro.
DR GO; GO:0004623; F:phospholipase A2 activity; IEA:UniProtKB-EC.
DR GO; GO:0090729; F:toxin activity; IEA:UniProtKB-KW.
DR GO; GO:0050482; P:arachidonic acid secretion; IEA:InterPro.
DR GO; GO:0016042; P:lipid catabolic process; IEA:UniProtKB-KW.
DR GO; GO:0006644; P:phospholipid metabolic process; IEA:InterPro.
DR CDD; cd00125; PLA2c; 1.
DR Gene3D; 1.20.90.10; -; 1.
DR InterPro; IPR001211; PLipase_A2.
DR InterPro; IPR033112; PLipase_A2_Asp_AS.
DR InterPro; IPR016090; PLipase_A2_dom.
DR InterPro; IPR036444; PLipase_A2_dom_sf.
DR InterPro; IPR033113; PLipase_A2_His_AS.
DR PANTHER; PTHR11716; PTHR11716; 1.
DR Pfam; PF00068; Phospholip_A2_1; 1.
DR PRINTS; PR00389; PHPHLIPASEA2.
DR SMART; SM00085; PA2c; 1.
DR SUPFAM; SSF48619; SSF48619; 1.
DR PROSITE; PS00119; PA2_ASP; 1.
DR PROSITE; PS00118; PA2_HIS; 1.
PE 1: Evidence at protein level;
KW 3D-structure; Blood coagulation cascade inhibiting toxin; Calcium;
KW Disulfide bond; Hemostasis impairing toxin; Hydrolase; Lipid degradation;
KW Lipid metabolism; Metal-binding; Secreted; Signal; Toxin.
FT SIGNAL <1..1
FT /evidence="ECO:0000255"
FT PROPEP 2..7
FT /evidence="ECO:0000250"
FT /id="PRO_0000346751"
FT CHAIN 8..126
FT /note="Acidic phospholipase A2 4"
FT /id="PRO_5000092373"
FT ACT_SITE 54
FT /evidence="ECO:0000305|PubMed:16269164"
FT ACT_SITE 100
FT /evidence="ECO:0000305|PubMed:16269164"
FT BINDING 34
FT /ligand="Ca(2+)"
FT /ligand_id="ChEBI:CHEBI:29108"
FT /evidence="ECO:0000269|PubMed:16269164,
FT ECO:0007744|PDB:1YXH"
FT BINDING 36
FT /ligand="Ca(2+)"
FT /ligand_id="ChEBI:CHEBI:29108"
FT /evidence="ECO:0000269|PubMed:16269164,
FT ECO:0007744|PDB:1YXH"
FT BINDING 38
FT /ligand="Ca(2+)"
FT /ligand_id="ChEBI:CHEBI:29108"
FT /evidence="ECO:0000269|PubMed:16269164,
FT ECO:0007744|PDB:1YXH"
FT BINDING 55
FT /ligand="Ca(2+)"
FT /ligand_id="ChEBI:CHEBI:29108"
FT /evidence="ECO:0000269|PubMed:16269164,
FT ECO:0007744|PDB:1YXH"
FT DISULFID 18..78
FT /evidence="ECO:0000269|PubMed:16269164,
FT ECO:0007744|PDB:1YXH"
FT DISULFID 33..125
FT /evidence="ECO:0000269|PubMed:16269164,
FT ECO:0007744|PDB:1YXH"
FT DISULFID 35..51
FT /evidence="ECO:0000269|PubMed:16269164,
FT ECO:0007744|PDB:1YXH"
FT DISULFID 50..106
FT /evidence="ECO:0000269|PubMed:16269164,
FT ECO:0007744|PDB:1YXH"
FT DISULFID 57..99
FT /evidence="ECO:0000269|PubMed:16269164,
FT ECO:0007744|PDB:1YXH"
FT DISULFID 67..92
FT /evidence="ECO:0000269|PubMed:16269164,
FT ECO:0007744|PDB:1YXH"
FT DISULFID 85..97
FT /evidence="ECO:0000269|PubMed:16269164,
FT ECO:0007744|PDB:1YXH"
FT NON_TER 1
FT HELIX 9..19
FT /evidence="ECO:0007829|PDB:1YXH"
FT HELIX 25..28
FT /evidence="ECO:0007829|PDB:1YXH"
FT STRAND 29..31
FT /evidence="ECO:0007829|PDB:1YXH"
FT TURN 32..34
FT /evidence="ECO:0007829|PDB:1YXH"
FT STRAND 35..37
FT /evidence="ECO:0007829|PDB:1YXH"
FT HELIX 46..61
FT /evidence="ECO:0007829|PDB:1YXH"
FT TURN 69..71
FT /evidence="ECO:0007829|PDB:1YXH"
FT STRAND 76..79
FT /evidence="ECO:0007829|PDB:1YXH"
FT STRAND 82..85
FT /evidence="ECO:0007829|PDB:1YXH"
FT HELIX 91..109
FT /evidence="ECO:0007829|PDB:1YXH"
FT HELIX 114..116
FT /evidence="ECO:0007829|PDB:1YXH"
FT HELIX 121..124
FT /evidence="ECO:0007829|PDB:1YXH"
SQ SEQUENCE 126 AA; 14198 MW; 2D7D066D02EBD827 CRC64;
SNRPMPLNIY QFKNMIQCTV PSRSWWDFAD YGCYCGRGGS GTPVDDLDRC CQVHDNCYNQ
AQEITGCRPK WKTYTYECSQ GTLTCKGRNN ACAATVCDCD RLAAICFAGA PYNDNNYNID
LKARCQ
